Investigation of clinical efficacy of aflicbercept in patients with polypoidal choroidal vasculopathy (PCV) with resistance of ranibizumab
Latest Information Update: 06 Dec 2016
At a glance
- Drugs Aflibercept (Primary)
- Indications Polypoidal choroidal vasculopathy
- Focus Therapeutic Use
- Sponsors Bayer Yakuhin
- 02 Dec 2016 Status changed from recruiting to discontinued.
- 21 Jan 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan
- 09 Dec 2013 New trial record